About Reata Pharmaceuticals (NASDAQ:RETA)

Reata Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on identifying, developing and commercializing product candidates that modulate the activity of regulatory proteins involved in the biology of mitochondrial function, oxidative stress, and inflammation to address the unmet medical needs of patients with a range of serious or life-threatening diseases. The Company's lead product candidates include bardoxolone methyl, which is being studied in Phase III trial for the treatment of pulmonary arterial hypertension (PAH), associated with connective tissue disease (CTD-PAH), as well as a Phase II trial for the treatment of pulmonary hypertension due to interstitial lung disease (PH-ILD), and PAH, each of which are subsets of pulmonary hypertension (PH), Omaveloxolone, which is in Phase II clinical development for the treatment of multiple diseases, including Friedreich's ataxia, mitochondrial myopathies and metastatic melanoma.

Receive RETA News and Ratings via Email

Sign-up to receive the latest news and ratings for RETA and its competitors with MarketBeat's FREE daily newsletter.

Profitability

Miscellaneous

Reata Pharmaceuticals (NASDAQ:RETA) Frequently Asked Questions

What is Reata Pharmaceuticals' stock symbol?

Reata Pharmaceuticals trades on the NASDAQ under the ticker symbol "RETA."

How were Reata Pharmaceuticals' earnings last quarter?

Reata Pharmaceuticals Inc (NASDAQ:RETA) announced its earnings results on Monday, November, 13th. The company reported ($0.50) earnings per share for the quarter, missing analysts' consensus estimates of ($0.39) by $0.11. The firm had revenue of $12.60 million for the quarter, compared to analysts' expectations of $12.54 million. The business's revenue for the quarter was up .0% on a year-over-year basis. View Reata Pharmaceuticals' Earnings History.

Where is Reata Pharmaceuticals' stock going? Where will Reata Pharmaceuticals' stock price be in 2017?

8 equities research analysts have issued twelve-month price targets for Reata Pharmaceuticals' stock. Their forecasts range from $43.00 to $78.00. On average, they anticipate Reata Pharmaceuticals' share price to reach $54.71 in the next year. View Analyst Ratings for Reata Pharmaceuticals.

What are Wall Street analysts saying about Reata Pharmaceuticals stock?

Here are some recent quotes from research analysts about Reata Pharmaceuticals stock:

1. According to Zacks Investment Research, "Reata Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It is engaged in identifying, developing and commercializing product candidates which modulate the activity of regulatory proteins involved in the biology of mitochondrial function, oxidative stress and inflammation to address the unmet medical needs of serious or life-threatening diseases. Reata Pharmaceuticals, Inc. is based in Irving, United States. " (11/16/2017)

3. Piper Jaffray Companies analysts commented, "We hosted Reata for investor meetings and came away with positive insights on its clinical progress in CTD-PAH, Friedreich's Ataxia, and other orphan disorders. On CTDPAH, we believe the CATALYST trial is progressing well and were reminded as to why we're confident in this capital-efficient trial design. In FA, we look forward to 'hypothesisgenerating' results in mid'17 which could demonstrate the first activity from omav' in a neurodegenerative condition ' potentially opening the door to a pivotal program in FA and/ or studies in other indications. To set up these results, we're hosting a KOL call on FA next Monday 4/3/17 ' contact your PJC rep for details. Overall, we expect Reata could conduct pivotal stage programs in 3+ orphan indications within the next 12 months, and continue to see this platform as under-valued compared to other multi-candidate, platform-enabled drug developers. In advance of clinical progress yet in 2017, we reiterate OW." (3/28/2017)

4. Stifel Nicolaus analysts commented, "Our positive thesis centers on what we see as blockbuster potential for lead asset bardoxolone methyl (BARD) in chronic kidney disease (CKD) caused by Alport syndrome. Yes, it's true that investors previously abandoned BARD in CKD after the P3 BEACON trial was halted in 2012 due to serious adverse events ' but we and our KOL consultants believe the underlying causes behind the prior safety issues are now well characterized and understood - and importantly, are prospectively controlled for in ongoing clinical trials - and therefore unlikely to re-emerge. Strong BARD efficacy across multiple prior CKD trials makes us confident that the drug will work as expected when initial P2 data are announced in 2H17. We are also sanguine on the BARD opportunity in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH), with P3 data expected in 1H18. Over the next 12-18 months we see four distinct clinical catalysts that hold potential for significant value creation ' and we recommend investors go long ahead of them." (2/22/2017)

5. Robert W. Baird analysts commented, "Though Reata's lead asset, bardoxolone methyl, has been plagued by safety concerns in the past, we think the company has gotten its groove back. With multiple readouts over the next two years in high unmet need indications and a valuation implying more failures than successes, we think the stock is significantly undervalued and see potential for upward momentum over the next 12-18 months. Initiating at Outperform with a $43 price target." (1/24/2017)

When did Reata Pharmaceuticals IPO?

(RETA) raised $60 million in an initial public offering (IPO) on Thursday, May 26th 2016. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. Citigroup, Cowen and Company and Piper Jaffray served as the underwriters for the IPO.

Who sold Reata Pharmaceuticals stock? Who is selling Reata Pharmaceuticals stock?

Reata Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co.. Company insiders that have sold Reata Pharmaceuticals company stock in the last year include A/S Novo and Abbvie Inc. View Insider Buying and Selling for Reata Pharmaceuticals.

How do I buy Reata Pharmaceuticals stock?

Shares of Reata Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Reata Pharmaceuticals' stock price today?

One share of Reata Pharmaceuticals stock can currently be purchased for approximately $25.22.

How big of a company is Reata Pharmaceuticals?

Reata Pharmaceuticals has a market capitalization of $608.17 million and generates $49.86 million in revenue each year. The company earns $-6,220,000.00 in net income (profit) each year or ($1.53) on an earnings per share basis. Reata Pharmaceuticals employs 75 workers across the globe.

MarketBeat Community Rating for Reata Pharmaceuticals (RETA)

MarketBeat's community ratings are surveys of what our community members think about Reata Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Reata Pharmaceuticals (NASDAQ:RETA) Analysts' Consensus Rating

MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.

MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.